<DOC>
	<DOC>NCT00851045</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with irinotecan, 5-FU and leucovorin in the second-line treatment of subject with metastatic colorectal cancer</brief_summary>
	<brief_title>Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>ECOG Performance Status (PS) ≤1 Histologically or cytologically confirmed, unresectable metastatic colorectal cancer Measurable disease by RECIST guidelines Evidence of disease progression following firstline therapy with a fluoropyrimidine, oxaliplatin, and bevacizumab (≤ 8 weeks since last dose) Available paraffin embedded tumor tissue Willing to give a whole blood sample for the study of proteins and genetic polymorphisms Less than 28 days elapsed since major surgery at time of randomization Known CNS metastases Excessive risk of bleeding (including use of therapeutic anticoagulation other than low dose aspirin) and history of thrombotic or embolic cerebrovascular accident Uncontrolled hypertension Clinically significant cardiovascular disease History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within the past 6 months Serious nonhealing wound, active peptic ulcer, nonhealing bone fracture, or bleeding skin metastasis Known HIV Positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>